Axonal degeneration in systemic sclerosis can be reverted by factors improving tissue oxygenation [4]

Rheumatology

Volumn 46, Issue 11, 2007, Pages 1739-1741

  Provitera, Vincenzo ^a   Nolano, M ^a   Pappone, N ^a   Lubrano, E ^a   Stancanelli, A ^a   Lanzillo, B ^a   Santoro, L ^b  

^a IRCCS   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST;

ADULT; AGED; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; LETTER; MULTIPLE CYCLE TREATMENT; NERVE FIBER DEGENERATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SKIN BIOPSY; SKIN BLOOD VESSEL; SKIN NERVE; SYSTEMIC SCLEROSIS; THREE DIMENSIONAL IMAGING; TISSUE OXYGENATION;

ADULT; AGED; AXONS; FEMALE; HUMANS; ILOPROST; MIDDLE AGED; NERVE DEGENERATION; OXYGEN CONSUMPTION; SCLERODERMA, SYSTEMIC; SKIN; VASODILATOR AGENTS;

EID: 35548969821     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem251     Document Type: Letter

References (10)

1. Hietaharju A, Jäaskelainen S, Kalimo H, Hletarinta M. Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma). Muscle Nerve 1993;16:1204-12.
2. Provitera V, Nolano M, Pappone N et al. Distal degeneration of sensory and autonomic cutaneous nerve fibres in systemic sclerosis. Ann Rheum Dis 2005;64:1524-6.
3. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
4. LeRoy EC, Black C, Fleishmajer R et al. Scleroderma (systemic sclerosis): Classification subsets and pathogenesis. J Rheumatol 1988;15:202-5.
5. Nolano M, Provitera V, CriSci C et al. Quantification of myelinated endings and mechanoreceptors in human digital skin. Ann Neurol 2003;54:197-205.
6. Caramaschi P, Biasi D, Canestrini S et al. Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost. Joint Bone Spine 2006;73:57-61.
7. Mirenda F, La Spada M, Baccellieri D, Stilo F, Benedetto F, Spinelli F. Iloprost infusion in diabetic patients with peripheral arterial occlusive disease and foot ulcers. Chir Ital 2005;57:731-5.
8. Ciuffetti G, Sokola E, Lombardini R, Pasquallini L Pirro M, Mannanno E. The influence of iloprost on blood rheology and tissue, perfusion in patients with intermittent claudication. Kardiol Pol 2003;59:197-204.
9. Faggioli P, Giani M, Mazzone, A. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis. Clin Exp Rheumatol 2006;24:220-1.
10. Ohno A, Kanazawa A, Tanaka A, Miwa T, Ito H. Effect of a prostaglandin 12 derivative (iloprost) on peripheral neuropathy of diabetic rats. Diabetes Res Clin Pract 1992;18:123-30.